Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Kraken Zone Discovery Unlocks Significant Value (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Eisai Co Ltd (PK) ESAIY

Alternate Symbol(s):  ESALF

Healthcare Drug Manufacturers - Specialty & Generic
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is... see more

Recent & Breaking News (PINL:ESAIY)

Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

ACN Newswire June 23, 2021

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate

ACN Newswire June 18, 2021

Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

ACN Newswire June 14, 2021

Eisai Receives Special Prize at Platinum Career Award 2021

ACN Newswire June 9, 2021

Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM

ACN Newswire June 8, 2021

Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib

ACN Newswire June 7, 2021

Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

ACN Newswire May 31, 2021

Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

ACN Newswire May 19, 2021

Eisai and National Cancer Center Commence Joint Research and Development Project

ACN Newswire May 14, 2021

Eisai's Statement of Commitment for Carbon Neutrality by 2040

ACN Newswire May 10, 2021

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan

ACN Newswire April 23, 2021

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

ACN Newswire April 23, 2021

Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease

ACN Newswire April 19, 2021

Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting

ACN Newswire April 14, 2021

Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021

ACN Newswire April 12, 2021

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

ACN Newswire March 31, 2021

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

ACN Newswire March 31, 2021

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

ACN Newswire March 25, 2021

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

ACN Newswire March 23, 2021

Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

ACN Newswire March 22, 2021

Podcasts